QSPainRelief-STRAT

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic PainAnalgesiaAdverse Drug EventDrug Interaction
Interventions
COMBINATION_PRODUCT

Opioid drug + CNS-acting add-on drug

Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).

All Listed Sponsors
collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

Université Catholique de Louvain

OTHER

NCT06244706 - QSPainRelief-STRAT | Biotech Hunter | Biotech Hunter